• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

用于治疗 COVID-19 诱导的代谢并发症的 ACE2 酶激活剂高通量筛选方案。

Protocol for high-throughput screening of ACE2 enzymatic activators to treat COVID-19-induced metabolic complications.

机构信息

National Supercomputer Center in Guangzhou, School of Computer Science and Engineering, Sun Yat-sen University, Guangzhou, Guangdong 510006, China.

Division of Vascular Surgery, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China; National-Guangdong Joint Engineering Laboratory for Diagnosis and Treatment of Vascular Diseases, The First Affiliated Hospital of Sun Yat-sen University, Guangzhou, Guangdong 510080, China.

出版信息

STAR Protoc. 2022 Aug 4;3(3):101641. doi: 10.1016/j.xpro.2022.101641. eCollection 2022 Sep 16.

DOI:10.1016/j.xpro.2022.101641
PMID:36035796
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC9350712/
Abstract

Drug repositioning represents a cost- and time-efficient strategy for drug development. Here, we present a workflow of screening of ACE2 enzymatic activators to treat COVID-19-induced metabolic complications. By using structure-based virtual screening and signature-based off-target effect identification via the Connectivity Map database, we provide a ranked list of the repositioning candidates as potential ACE2 enzymatic activators to ameliorate COVID-19-induced metabolic complications. The workflow can also be applied to other diseases with ACE2 as a potential target. For complete details on the use and execution of this protocol, please refer to Li et al. (2022).

摘要

药物重定位是一种具有成本效益和高效率的药物开发策略。在这里，我们提出了一种筛选 ACE2 酶激活剂以治疗 COVID-19 诱导的代谢并发症的工作流程。通过使用基于结构的虚拟筛选和基于 Connectivity Map 数据库的特征基靶标效应识别，我们提供了一个重新定位候选药物作为潜在 ACE2 酶激活剂的排名列表，以改善 COVID-19 诱导的代谢并发症。该工作流程也可应用于其他以 ACE2 为潜在靶点的疾病。有关此方案的使用和执行的详细信息，请参阅 Li 等人（2022 年）。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/b487b8a18fed/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/5d2f40c1b0ad/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/50f2ee625726/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/2cc129a30552/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/b487b8a18fed/gr3.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/5d2f40c1b0ad/fx1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/50f2ee625726/gr1.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/2cc129a30552/gr2.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/74e9/9420397/b487b8a18fed/gr3.jpg

相似文献

1
Protocol for high-throughput screening of ACE2 enzymatic activators to treat COVID-19-induced metabolic complications.用于治疗 COVID-19 诱导的代谢并发症的 ACE2 酶激活剂高通量筛选方案。
STAR Protoc. 2022 Aug 4;3(3):101641. doi: 10.1016/j.xpro.2022.101641. eCollection 2022 Sep 16.
2
An drug repositioning workflow for host-based antivirals.基于宿主的抗病毒药物的药物重定位工作流程。
STAR Protoc. 2021 Jul 7;2(3):100653. doi: 10.1016/j.xpro.2021.100653. eCollection 2021 Sep 17.
3
Detection of SARS-CoV-2 spike protein binding to ACE2 in living cells by TR-FRET.通过时间分辨荧光共振能量转移（TR-FRET）检测活细胞中 SARS-CoV-2 刺突蛋白与 ACE2 的结合。
STAR Protoc. 2022 Mar 18;3(1):101024. doi: 10.1016/j.xpro.2021.101024. Epub 2021 Nov 22.
4
A computational protein design protocol for optimization of the SARS-CoV-2 receptor-binding-motif affinity for human ACE2.一种用于优化 SARS-CoV-2 受体结合基序对人 ACE2 亲和力的计算蛋白质设计方案。
STAR Protoc. 2022 Mar 3;3(2):101254. doi: 10.1016/j.xpro.2022.101254. eCollection 2022 Jun 17.
5
The spike-ACE2 binding assay: An in vitro platform for evaluating vaccination efficacy and for screening SARS-CoV-2 inhibitors and neutralizing antibodies.刺突蛋白-ACE2 结合分析：评估疫苗效力和筛选 SARS-CoV-2 抑制剂及中和抗体的体外平台。
J Immunol Methods. 2022 Apr;503:113244. doi: 10.1016/j.jim.2022.113244. Epub 2022 Feb 23.
6
ACE2 chromogenic immunostaining protocol optimized for formalin-fixed paraffin-embedded human tissue sections.用于福尔马林固定石蜡包埋人组织切片的 ACE2 显色免疫组化染色方案。
STAR Protoc. 2021 Sep 17;2(3):100696. doi: 10.1016/j.xpro.2021.100696. Epub 2021 Jul 21.
7
Competitive SARS-CoV-2 Serology Reveals Most Antibodies Targeting the Spike Receptor-Binding Domain Compete for ACE2 Binding.竞争性 SARS-CoV-2 血清学研究表明，大多数针对刺突受体结合域的抗体竞争与 ACE2 结合。
mSphere. 2020 Sep 16;5(5):e00802-20. doi: 10.1128/mSphere.00802-20.
8
In silico exploration of small-molecule α-helix mimetics as inhibitors of SARS-COV-2 attachment to ACE2.计算机模拟探索小分子 α-螺旋类似物作为 SARS-CoV-2 与 ACE2 结合抑制剂。
J Biomol Struct Dyn. 2022 Mar;40(4):1546-1557. doi: 10.1080/07391102.2020.1830175. Epub 2020 Oct 7.
9
Angiotensin-Converting Enzyme 2 (ACE2) in the Pathogenesis of ARDS in COVID-19.血管紧张素转换酶 2（ACE2）在 COVID-19 所致急性呼吸窘迫综合征发病机制中的作用。
Front Immunol. 2021 Dec 22;12:732690. doi: 10.3389/fimmu.2021.732690. eCollection 2021.
10
Molecular basis for drug repurposing to study the interface of the S protein in SARS-CoV-2 and human ACE2 through docking, characterization, and molecular dynamics for natural drug candidates.通过对接、表征和分子动力学研究天然候选药物与严重急性呼吸综合征冠状病毒2（SARS-CoV-2）的S蛋白和人类血管紧张素转换酶2（ACE2）界面之间关系的药物重新利用的分子基础。
J Mol Model. 2020 Nov 11;26(12):338. doi: 10.1007/s00894-020-04599-8.

本文引用的文献

1
Imatinib and methazolamide ameliorate COVID-19-induced metabolic complications via elevating ACE2 enzymatic activity and inhibiting viral entry.伊马替尼和氨苯蝶啶通过提高 ACE2 酶活性和抑制病毒进入来改善 COVID-19 引起的代谢并发症。
Cell Metab. 2022 Mar 1;34(3):424-440.e7. doi: 10.1016/j.cmet.2022.01.008. Epub 2022 Feb 11.
2
COVID-19 induces new-onset insulin resistance and lipid metabolic dysregulation via regulation of secreted metabolic factors.COVID-19 通过调节分泌的代谢因子诱导新发的胰岛素抵抗和脂质代谢失调。
Signal Transduct Target Ther. 2021 Dec 16;6(1):427. doi: 10.1038/s41392-021-00822-x.
3
Hyperglycemia without diabetes and new-onset diabetes are both associated with poorer outcomes in COVID-19.
高血糖而无糖尿病和新发糖尿病均与 COVID-19 的预后不良相关。
Diabetes Res Clin Pract. 2020 Sep;167:108382. doi: 10.1016/j.diabres.2020.108382. Epub 2020 Aug 25.
4
Extrapulmonary manifestations of COVID-19.COVID-19 的肺外表现。
Nat Med. 2020 Jul;26(7):1017-1032. doi: 10.1038/s41591-020-0968-3. Epub 2020 Jul 10.
5
Drug repositioning or target repositioning: A structural perspective of drug-target-indication relationship for available repurposed drugs.药物重新定位或靶点重新定位：现有重新利用药物的药物-靶点-适应症关系的结构视角
Comput Struct Biotechnol J. 2020 Apr 13;18:1043-1055. doi: 10.1016/j.csbj.2020.04.004. eCollection 2020.
6
Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19.COVID-19 患者支气管肺泡免疫细胞的单细胞景观。
Nat Med. 2020 Jun;26(6):842-844. doi: 10.1038/s41591-020-0901-9. Epub 2020 May 12.
7
A Next Generation Connectivity Map: L1000 Platform and the First 1,000,000 Profiles.下一代连接图谱：L1000平台及首批100万个图谱
Cell. 2017 Nov 30;171(6):1437-1452.e17. doi: 10.1016/j.cell.2017.10.049.
8
The role of renin-angiotensin system modulation on treatment and prevention of liver diseases.肾素-血管紧张素系统调节在肝脏疾病治疗和预防中的作用。
Peptides. 2014 Dec;62:189-96. doi: 10.1016/j.peptides.2014.10.005.
9
Angiotensin-converting enzyme 2 and angiotensin 1-7: novel therapeutic targets.血管紧张素转换酶 2 和血管紧张素 1-7：新的治疗靶点。
Nat Rev Cardiol. 2014 Jul;11(7):413-26. doi: 10.1038/nrcardio.2014.59. Epub 2014 Apr 29.
10
Drug repositioning by structure-based virtual screening.基于结构的虚拟筛选的药物重定位。
Chem Soc Rev. 2013 Mar 7;42(5):2130-41. doi: 10.1039/c2cs35357a. Epub 2013 Jan 4.